CLOVIS ONCOLOGY Forum: Community User: Maroni

Schön schön.. Wieder über 15... Hoffentlich nachhaltig!!

Zacks Investment Research upgraded shares ofClovis Oncology Inc. (NASDAQ:CLVS) from a hold rating to a buy rating in a report released on Thursday morning. Zacks Investment Research currently has $18.00 target price on the biopharmaceutical company’s stock. According to Zacks, “Clovis’ second quarter loss was narrower-than-expected. We are encouraged by the company's progress with its lead pipeline candidate, rucaparib. The company has submitted a rolling NDA for the candidate and is on track to file for EU approval in the fourth quarter of 2016. Approval would be a huge boost for the company given the immense commercial potential in the target market and the demand for PARP inhibitors. However, we remain concerned about Clovis’ dependence on just one candidate. The company has already suffered a huge setback on the regulatory front when it was informed by the FDA that the agency would issue a complete response letter for rociletinib. Based on this, the company decided to discontinue investment in rociletinib. Any further regulatory or pipeline setback would weigh heavily on the stock.”

http://www.stockrevealer.com/blog/2016/8/11/vn8kys2t13fddbrejyui0w0092gnyu

Hmmmm sieht eher nach schlechten Zahlen aus momentan

eigtl ein gutes Zeichen. ...das es vorher so anzieht,da wissen leider wiedermal einige mehr

Am Montag kommen dann nachbörslich die Zahlen...

klasse

super

Ek erreicht.... Juhu

Uiuiiii

einfach mal 2,3 Jahre liegen lassen

Clovis Oncology Inc. (NASDAQ:CLVS) will post its Q216 quarterly earnings results on Monday, August 8th. Analysts expect Clovis Oncology to post earnings of ($2.13) per share for the quarter. Individual that are interested in participating in the company’s earnings conference call can do so using this link. Clovis Oncology (NASDAQ:CLVS) last issued its quarterly earnings results on Thursday, May 5th. The biopharmaceutical company reported ($2.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.39) by $0.22. During the same quarter last year, the business earned ($1.86) earnings per share. The company’s revenue was up NaN% on a year-over-year basis. On average, analysts expect Clovis Oncology to post $-8.00 EPS for the current fiscal year and $-4.85 EPS for the next fiscal year. Shares of Clovis Oncology Inc. (NASDAQ:CLVS) opened at 15.23 on Thursday. The firm’s market capitalization is $584.60 million. The firm has a 50-day moving average of $14.09 and a 200 day moving average of $16.52. Clovis Oncology Inc. has a 52 week low of $11.57 and a 52 week high of $116.75. A number of equities research analysts have recently commented on CLVS shares. Mizuho reduced their price objective on shares of Clovis Oncology from $21.00 to $15.00 and set a “neutral” rating on the stock in a research note on Monday, April 11th. Piper Jaffray Cos. reissued a “neutral” rating and set a $18.00 target price on shares of Clovis Oncology in a research note on Tuesday, April 12th. Zacks Investment Research lowered shares of Clovis Oncology from a “hold” rating to a “sell” rating in a research note on Tuesday, April 12th. Stifel Nicolaus reissued a “buy” rating and set a $30.00 target price on shares of Clovis Oncology in a research note on Tuesday, April 12th. Finally, JPMorgan Chase & Co. lowered shares of Clovis Oncology from an “overweight” rating to a “neutral” rating and cut their target price for the stock from $42.00 to $15.00 in a research note on Wednesday, April 13th. Seven equities research analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $29.25. Clovis Oncology, Inc (Clovis) is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and additional international markets. The Company is developing three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib, an oral epidermal growth factor receptor (EGFR), is a mutant-selective covalent inhibitor that is in advanced clinical development for the treatment of non-small cell lung cancer.

sieht auf jeden FALL so aus

Chart. ..Ausbruch oder wie soll ich das verstehen?

https://t.co/NqjTkmASkQ

mal sehen wo die Richtung zum 8.8 hingeht...